Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21384533 | 1.00 | GAA (0.41) | GAAALDH1A1L3MBTL1THRBATM | |
| SCHEMBL23865508 | 0.86 | GAA (0.42) | GAAALDH1A1L3MBTL1THRBATM | |
| SCHEMBL27375319 | 0.81 | CHRM4 (0.46) | GAAALDH1A1L3MBTL1THRBATM | |
| SCHEMBL23368109 | 0.81 | CHRM4 (0.46) | GAAALDH1A1L3MBTL1THRBATM | |
| SCHEMBL29326520 | 0.80 | GAA (0.39) | GAAALDH1A1L3MBTL1THRBATM | |
| SCHEMBL21401562 | 0.80 | L3MBTL1 (0.39) | GAAALDH1A1L3MBTL1THRBATM | |
| SCHEMBL21384531 | 0.80 | L3MBTL1 (0.39) | GAAALDH1A1L3MBTL1THRBATM | |
| SCHEMBL29427120 | 0.79 | CHRM2 (0.44) | SMN1; SMN2CHRM1RECQLCHRM2 | |
| SCHEMBL22747737 | 0.79 | CHRM2 (0.44) | SMN1; SMN2CHRM1RECQLCHRM2 | |
| SCHEMBL22915089 | 0.79 | CHRM2 (0.44) | SMN1; SMN2CHRM1RECQLCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12398119-B2 | Piperazine azaspiro derivatives | PFIZER INC. (US) | 2025-08-26 | — | — | US | disclosed |
| CN-112154145-B | Piperazine azaspiro derivatives | 辉瑞大药厂 | 2023-10-17 | — | — | CN | disclosed |
| EP-4219464-A1 | PIPERAZINE AZASPIRO DERIVAVES | Pfizer Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4219464-A1 | PIPERAZINE AZASPIRO DERIVAVES | Pfizer Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230192654-A1 | PIPERAZINE AZASPIRO DERIVATIVES | PFIZER INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192654-A1 | PIPERAZINE AZASPIRO DERIVATIVES | PFIZER INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192654-A1 | PIPERAZINE AZASPIRO DERIVATIVES | PFIZER INC. | 2023-06-22 | — | — | US | disclosed |
| EP-3768669-B1 | PIPERAZINE AZASPIRO DERIVAVES | PFIZER (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-3768669-B1 | PIPERAZINE AZASPIRO DERIVAVES | PFIZER (US) | 2023-01-25 | — | — | EP | disclosed |
| US-11524954-B2 | Piperazine azaspiro derivatives | PFIZER INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-11524954-B2 | Piperazine azaspiro derivatives | PFIZER INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20210024497-A1 | PIPERAZINE AZASPIRO DERIVAVES | PFIZER INC. | 2021-01-28 | — | — | US | disclosed |
| US-20210024497-A1 | PIPERAZINE AZASPIRO DERIVAVES | PFIZER INC. | 2021-01-28 | — | — | US | disclosed |
| EP-3768669-A1 | PIPERAZINE AZASPIRO DERIVAVES | Pfizer Inc (US) | 2021-01-27 | — | — | EP | disclosed |
| WO-2019183636-A1 | PIPERAZINE AZASPIRO DERIVAVES | PFIZER INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019183636-A1 | PIPERAZINE AZASPIRO DERIVAVES | PFIZER INC. (US) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192654-A1 | PIPERAZINE AZASPIRO DERIVATIVES | CHRM1, CHRM2, CHRM5 | GAA 2320/4885ALDH1A1 1350/4885L3MBTL1 2496/4885 |
| US-12398119-B2 | Piperazine azaspiro derivatives | CHRM1, CHRM2, CHRM5 | GAA 2320/4885ALDH1A1 1350/4885L3MBTL1 2496/4885 |
| US-11524954-B2 | Piperazine azaspiro derivatives | CHRM1, CHRM2, CHRM5 | GAA 2320/4885ALDH1A1 1350/4885L3MBTL1 2496/4885 |
| US-20210024497-A1 | PIPERAZINE AZASPIRO DERIVAVES | CHRM1, CHRM2, CHRM5 | GAA 2560/4885ALDH1A1 906/4885L3MBTL1 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.